Clinical Trial Update: Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy [Phase 3]

View source ↗

Summary

This clinical trial update reports that a Phase 3 study evaluating three doses of SPM 927 (200, 400, and 600 mg/day) for painful distal diabetic neuropathy has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy
• Painful Diabetic Neuropathy

Drugs mentioned

• SPM 927 (SPM 927)

Snippet

Sponsor: UCB Pharma | Conditions: Diabetic Neuropathies | Phase 3 | Status: COMPLETED